

**Date:** May 24, 2024

**To**  
**BSE Limited**  
1st Floor, P.J. Towers,  
Dalal Street, Mumbai – 400001  
Scrip Code: **506642**

**To**  
**National Stock Exchange of India Limited**  
Exchange plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai-400051, India  
Symbol: **SADHNANIQ**

**Subject: Press Release under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

With reference to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Press Release titled “Sadhana Nitro Chem Ltd. Reports Robust Earnings for FY24, EBITDA Grows 96% YoY.”

You are requested to kindly take the afore-mentioned on record and oblige.

Thanking you,

**For SADHANA NITRO CHEM LIMITED**

**Nitin Rameshchandra Jani**  
**Company Secretary & Compliance Officer**  
**Membership No.: A4757**

**Corporate Office**

10, Bruce Street, 1st Floor,  
8/12, Homi Mody Street, Fort,  
Mumbai - 400001

**Factory Address**

47, MIDC, Roha - 402116.  
Dist. Raigad (M.S.)  
Dhatav, Maharashtra

**Registered Office**

Hira Baug, 1st Floor,  
Kasturba Chowk (C.P. Tank),  
Mumbai - 400 004. INDIA

## Sadhana Nitro Chem Ltd. Reports Robust Earnings for FY24, EBITDA Grows 96% YoY

### Key Consolidated Highlights (FY24)

Revenue from Operations	EBITDA	PAT
Rs. 190.05 Cr	Rs. 45.03 Cr	Rs. 4.08 Cr
↑ 33% YoY	↑ 96% YoY	↑ 28% YoY

**Mumbai, 21 May 2024:** Sadhana Nitro Chem Ltd., a prominent manufacturer specializing in intermediate specialty chemicals, in its board meeting held on May 17, 2024 has approved the audited Financial Results of the Company for the quarter and year ended on 31 March 2024. The company also approved a 15% Dividend for FY24.

### Consolidated Financial Statement Highlights

Particulars (Rs. Crores)*	FY24	FY23	YoY%	Q4FY24	Q4FY23	YoY%
Revenue from Operations	190.05	143.33	<b>+33%</b>	64.55	48.16	<b>+34%</b>
EBITDA	45.03	23.01	<b>+96%</b>	11.76	10.02	<b>+17%</b>
PBT	12.83	5.65	<b>+127%</b>	4.17	3.07	<b>+36%</b>
PAT	4.08	3.18	<b>+28%</b>	0.52	1.76	<b>-70%</b>

\*Financial Figures & percentages have been rounded and reorganized for efficient presentation and understanding

### Commenting on the Q4FY24 & FY24 Performance, Management added,

*"We are pleased to report the impressive financial performance of our company for both the quarter and year ended 31 March 2024. In Q4FY24, our Revenue from Operations grew by a robust 34%, reaching Rs. 64.55 Cr, while our EBITDA saw a commendable increase of 17%, amounting to Rs. 11.76 Cr. Profit Before Tax (PBT) increased by 36% to Rs. 4.17 crore. As a result of tax adjustments, our Profit After Tax (PAT) decreased by 70% from Rs. 1.76 Cr in Q3FY24 to Rs. 0.52 Cr in Q4FY24.*

*For the full year FY24, our company demonstrated remarkable growth and resilience. Revenue from Operations increased by 33%, reaching Rs. 190.05 Cr. Our EBITDA surged by 96%, amounting to Rs. 45.03 Cr, reflecting our continued focus on operational efficiency and cost management. Additionally, our PBT jumped by an impressive 127% to Rs. 12.83 Cr, while our PAT increased by 28%, totalling Rs. 4.08 Cr.*

*In light of these results, we are pleased to announce a dividend of 15% for FY24, underscoring our commitment to delivering value to our shareholders. Furthermore, we are in the process of finalizing the proposed rights issue, not exceeding Rs. 49.95 Crores. Keeping in mind feedback received from several shareholders we are working to finalise pricing (with premium), the determination of the entitlement ratio, and other details to align with SEBI guidelines as well as ensure delivering value to our shareholders*

*In the previous quarter, we are proud to announce, Dr. Mansukh Mandaviya, Union Minister for Chemicals & Fertilizers and Health & Family Welfare virtually inaugurated Sadhana Nitro Chem Ltd.'s Para Amino Phenol (pAP) bulk drug plant, amongst 26 other greenfield bulk drug park projects and 13 greenfield manufacturing plants for medical devices.*

*This achievement results from the dedication, hard work, and support of our entire team, as well as our customers, partners, and shareholders. We remain committed to operating excellence and to leveraging our strengths as we move forward. We are confident in our ability to build on this success and drive sustained growth in the future.”*

### **Management Note on Vision and Future Plans**

*We are pleased to share our vision and strategic plans as we look forward to building on our recent successes and driving sustainable growth.*

**Expansion and Output Growth:** *The expansion of our ODB2 capacity from 550 TPA to 2200 TPA last year has been a significant milestone. This expansion has not only enabled us to steadily increase our output but also to address competitive pricing pressures from China by compensating with higher volumes. Our backward integration strategy has solidified our position as a prominent supplier of ODB2 to paper companies worldwide. With approvals from all major paper companies, we are seeing steady growth in our market share, positioning us in a healthy and sustainable position for the future.*

**Focus on Continuous Production:** *With the quality and output of our Para-Amino Phenol (pAP) reaching desirable levels, our focus now shifts towards expanding our capacity and achieving continuous production downstream. Following the successful migration of the product synthesis from batch to continuous production, this strategy will help us grow both our top and bottom lines steadily over the coming years. In adapting our processes from batch to continuous processing is a testament to our engineering strengths.*

**Environmental Consciousness:** *Environmental consciousness remains a cornerstone of our operational ethos. All our new products are environmentally friendly and achieve zero effluent discharge. We are committed to ensuring that within the next 12-18 months, our legacy products will also migrate to zero discharge. Our dedication to sustainability is further exemplified by our initiatives in solar energy and green hydrogen for our hydrogenation products. We are excited to see the growth of these green initiatives in the years to come.*

**Portfolio Expansion:** *In the coming year, we expect to see significant growth in our pharmaceutical portfolio, with new additions such as Paracetamol and other products. This expansion is part of our strategic initiative to diversify and enhance our product offerings in high-demand sectors.*

**Innovative Applications:** *We are seeing an increasing application of several of our legacy products, particularly m-Aminophenol in new-age applied material sciences. We are actively collaborating with our customers to grow these applications and seed new ones, just as we have successfully done with our existing products. This collaborative approach ensures that we remain at the forefront of innovation and industry developments.*

### **Value Engineering**

*Over the past year, we have dedicated significant efforts to value engineering, focusing on enhancing the cost structure of our legacy products through innovative processes and advanced technologies. These developments are pivotal in our long-term sustainability strategy, providing us with a competitive edge over Chinese manufacturers. By optimizing production efficiency and reducing costs, we are reinforcing our commitment to operational excellence and strengthening our market position.*

*In conclusion, our strategic initiatives are well-aligned with our vision of sustainable growth, operational excellence, and environmental stewardship. We remain committed to leveraging our strengths, embracing innovation, and delivering value to our stakeholders as we move forward.*

*By incorporating this vision into our earnings release, we aim to provide a clear roadmap for our future, emphasizing our commitment to growth, sustainability, and innovation.*

**About Sadhana Nitro Chem Ltd.**

Established in 1973, Sadhana Nitro Chem Ltd., stands as a prominent manufacturer specializing in intermediate specialty chemicals. Sadhana Nitro Chem Ltd. operates from its state-of-the-art manufacturing facility situated in the Roha spread over 22 acres including 17 acres of MIDC land. Sadhana Nitro Chem Ltd.'s Facility is the 2<sup>nd</sup> Plant in the world to manufacture pAP from Nitrobenzene, with the company receiving Approval from the Maharashtra Pollution Control Board (MPCB) for consent to establish. The company has been awarded from the PLI scheme for manufacturing 36000 TPA of PAP in 2021, with the current production run rate of 3000 TPA being scaled rapidly. pAP is used in the manufacturing of Paracetamol, amongst other prescription drugs. The company is a government-recognized 2-Star Golden Export House, with 80% of the company's sales being dedicated to exports to highly developed markets, such as Japan, China, Switzerland, the United States, Germany, other parts of Europe, South Korea and more. Sadhana Nitro Chem Ltd takes pride in its extensive client portfolio, which predominantly comprises multinational conglomerates such as L'Oreal, Bayer Crop Science, Huntsman Advanced Materials, Teijin, Mitsui Chemicals, IPCA, Ricoh Paper, Koehler Paper, and Mitsubishi Paper, among others. The company's versatile product line finds applications spanning various industries, including Agro Chemicals, Aramide Fibre, Pharmaceuticals, Developers, Hair Colors, Dyes, Specialized Resins, Performance Chemicals, Optical Brightening Agents, Rubber Chemicals, Aerospace, Electronic Chemicals, Military Applications, Thermal Paper Intermediates, and more. The company is committed to quality and social responsibility, holding ISO certifications for ISO 9001:2008, ISO 14001:2004, OHSAS 18001:2007, and SA (8000). Sadhana Nitro Chem Ltd is listed on both BSE: 506642 and NSE: SADHNANIQ, and is currently celebrating its 50<sup>th</sup> year as a publicly listed company.

**Investor Relations Advisor:**

Brijesh K.

**Impress Strategic Communications Private Limited**

Email: [sadhananitro@impressir.com](mailto:sadhananitro@impressir.com)

**Disclaimer:**

Certain statements in this release concerning our future growth prospects are forward-looking statements, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, our ability to successfully implement our strategy, our research and development efforts, changes in the value of the Rupee and other currency changes, intense competition in the industry including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, industry segment concentration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks or system failures, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, withdrawal of governmental fiscal incentives, political instability and regional conflicts, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property and general economic conditions affecting our industry. Sadhana Nitro Chem Limited may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the Securities and Exchange Board of India, Stock Exchange and our reports to shareholders. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the company.